

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
LCM	A1	4,762,705	08/09/88	Rubin	424	85	03/29/84
LCM	A2	5,057,302	10/15/91	Johnson <i>et al.</i>	424	1.1	01/04/88
LCM	A3	5,100,885	03/31/92	Abrams <i>et al.</i>	514	184	08/01/89
LCM	A4	5,169,858	12/08/92	Rubin	514	365	02/26/86
LCM	A5	5,385,933	01/31/95	Rabinovitz <i>et al.</i>	514	499	06/19/92
LCM	A6	5,563,132	10/08/96	Bodaness	514	185	06/21/94

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C1	Allen and Solomons, "Normal intestinal mechanisms in the absorption of copper," In: <i>Absorption and Malabsorption of Mineral Nutrients</i> , Solomons and Rosenberg, Eds., Alan R. Liss, Inc., New York, 12:199-229, 1984.
LCM	C2	Alpern-Elran and Brem, "Angiogenesis in human brain tumors: inhibition by copper depletion," <i>Neurological Surgery</i> , pp. 498-500, publication date unknown.
LCM	C3	Brem <i>et al.</i> , "Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain," <i>Neurosurgery</i> , 26:391-396, 1990.

EXAMINER:

Lugh C. Maier

DATE CONSIDERED:

4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C4	Brem <i>et al.</i> , "Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic colactor," <i>Am. J. Pathol.</i> , 137(5):1121-1142, 1990.
LCM	C5	Brem <i>et al.</i> , "Tetrathiomolybdate, a chelator of copper, reduces intracerebral peritumoral edema in rats," <i>Proceeding of the American Association for Cancer Research</i> , 33:76, Abstract 455, 1992.
LCM	C6	Bremner <i>et al.</i> , "Copper metabolism in rats given di-or trithiomolybdates," <i>J. Inorg. Biochem.</i> , 16: 109, 1982.
LCM	C7	Brewer and Yuzbasiyan-Gurkan, "Wilson Disease," <i>Medicine</i> , 71(3):139-164, 1992.
LCM	C8	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease," In: <i>Textbook of Clinical Neuropsychopharmacology and Therapeutics</i> , 2nd Edition, Klawans <i>et al.</i> , Eds., Raven Press, New York, pp. 191-205, 1992.
LCM	C9	Brewer and Yuzbasiyan-Gurkan, "Wilson's disease: an update, with emphasis on new approaches to treatment," <i>Dig. Dis.</i> , 7(4):178-193, 1989.
LCM	C10	Brewer, "Interactions of zinc and molybdenum with copper in therapy of Wilson's disease," <i>Nutr.</i> , 11(1 Suppl):114-116, 1995.
LCM	C11	Brewer, "Practical recommendations and new therapies for Wilson's disease," <i>Drugs</i> , 50(2):240-249, 1995.
LCM	C12	Brewer, "Thiomolybdates in the treatment of Wilson's disease," <i>Arch. Neurol.</i> , 49: 132-133, 1992.
LCM	C13	Brewer, "Zinc in the Treatment of Wilson's Disease," <i>Nutrition and the M.D.</i> 19(12): 1993.
LCM	C14	Brewer <i>et al.</i> , "Treatment of Wilson's disease with ammonium tetrathiomolybdate. I Initial therapy in 17 neurologically affected patients," <i>Arch. Neurol.</i> , 51(6):545-554, 1994.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C15	Brewer <i>et al.</i> , "Use of zinc acetate to treat copper toxicosis in dogs," <i>JAVMA</i> 201:564-568, 1992.
LCM	C16	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis," <i>J. Lab. Clin. Med.</i> , 123:849-858, 1994.
LCM	C17	Brewer <i>et al.</i> , "Initial therapy of Wilson's Disease patients with tetrathiomolybdate," <i>Arch. Neurol.</i> , 48(1):42-47, 1991.
LCM	C18	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc III. Prevention of reaccumulation of hepatic copper," <i>J. Lab. Clin. Med.</i> , 109:526-531, 1987.
LCM	C19	Brewer <i>et al.</i> , "Oral zinc therapy for Wilson's disease," <i>Annals Int. Med.</i> , 99:314-320, 1983.
LCM	C20	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc: IV. Efficacy monitoring using urine and plasma copper," <i>Proc. Soc. Exper. Biol. Med.</i> , 184:446-455, 1987.
LCM	C21	Brewer <i>et al.</i> , "Treatment of Wilson's disease with ammonium tetrathiomolybdate II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy," <i>Arch. Neurol.</i> , 53:1017-1025, 1996.
LCM	C22	Brewer <i>et al.</i> , "The use of <sup>64</sup> copper measurements to diagnose canine copper toxicosis," <i>J. Vet. Int. Med.</i> , 6:41-43, 1992.
LCM	C23	Brewer <i>et al.</i> , "Worsening of neurological syndrome upon initial treatment of Wilson's Disease patients with penicillamine," <i>Arch. Neurol.</i> , 44:490-493, 1987.
LCM	C24	Brewer <i>et al.</i> , "Development of neurologic symptoms in a patient with asymptomatic Wilson's disease treated with penicillamine," <i>Arch. Neurol.</i> , 51:304-305, 1994.

EXAMINER:

Leigh C. Maier

DATE CONSIDERED:

4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C25	Brewer <i>et al.</i> , "Zinc therapy of Wilson's Disease VIII. Dose response studies," <i>J. Trace Elem. Exp. Med.</i> , 3:227-234, 1990.
LCM	C26	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc: IX. Response of serum lipids," <i>J. Lab. Clin. Med.</i> , 118:466-470, 1991.
LCM	C27	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XI. Interaction with other anticopper agents," <i>J. Amer. Coll. Nut.</i> , 12(1):26-30, 1993.
LCM	C28	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc XII. Dose regimen requirements," <i>Amer. J. Med. Sci.</i> , 305: (4):199-202, 1993.
LCM	C29	Brewer <i>et al.</i> , "Molecular genetics and zinc-copper interactions in human Wilson's Disease and canine copper toxicosis," In: <i>Essential and Toxic Trace Elements in Human Health and Disease: An Update</i> , Prasad, Ed., Allan R. Liss, New York, PCBR 380:129-145, 1993.
LCM	C30	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with zinc VI. Initial treatment studies," <i>J. Lab. Clin. Med.</i> , 114: 633-638, 1989.
LCM	C31	Brewer <i>et al.</i> , "Treatment of Wilson's Disease," <i>Sem. Neurol.</i> , 7:209-220, 1987.
LCM	C32	Coucouvanis <i>et al.</i> , "An inorganic functional group approach to the systematic synthesis and reactivity studies of binuclear Mo/S and Mo/S/O complexes," <i>Polyhedron</i> , 8(13/14):1705-1716, 1989.
LCM	C33	Coucouvanis <i>et al.</i> , "Dinuclear Fe-Mo-S complexes containing the FeS <sub>2</sub> Mo core. Syntheses, ground-state electronic structures, and crystal and molecular structures of the [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [(C <sub>6</sub> H <sub>5</sub> S) <sub>2</sub> FeS <sub>2</sub> MoS <sub>2</sub> ], [(C <sub>2</sub> H <sub>5</sub> ) <sub>4</sub> N] <sub>2</sub> [(C <sub>6</sub> H <sub>5</sub> S) <sub>2</sub> FeS <sub>2</sub> WS <sub>2</sub> ], and [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [(S) <sub>5</sub> FeS <sub>2</sub> MS <sub>2</sub> ] (M = Mo, W) complexes," <i>Inorg. Chem.</i> , 22:293-308, 1983.
LCM	C34	Coucouvanis <i>et al.</i> , "Heterodinuclear Di-μ-sulfido bridged dimers containing iron and molybdenum or tungsten. Structures of (PhP) <sub>2</sub> (FeMS <sub>9</sub> ) complexes (M = Mo, W)," <i>J. Am. Chem. Soc.</i> , 102:1730-1732, 1980.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C35	Coucouvanis <i>et al.</i> , "Successful isolation of a reduced tetrathiomallate complex. Synthesis and structural characterization of the $[(\text{MoS}_4)_2\text{Fe}]^{3-}$ trianion," <i>J. Am. Chem. Soc.</i> , 102:6644-6646, 1980.
LCM	C36	Coucouvanis <i>et al.</i> , "Synthesis and structural characterization of $[(\text{No})_2\text{FeS}_2\text{MoS}_2]^{2-}$ a dinitrosyl complex containing the $\text{FeS}_2\text{MoS}_2$ core," <i>Inorg. Chim. Acta</i> , 53:L135-L137, 1981.
LCM	C37	Coucouvanis <i>et al.</i> , "Synthesis of thiomolybdenyl complexes with $[\text{Mo}_2(\text{S})_2(\text{O})_2]^{2+}$ cores and substitutionally labile ligands. Crystal and molecular structure of the $[\text{Mo}_2\text{O}_2\text{S}_4(\text{DMF})_3]$ complex," <i>Inorg. Chem.</i> , 27:3272-3273, 1988.
LCM	C38	Coucouvanis <i>et al.</i> , "Trinuclear Fe-M-S complexes containing a linear Fe-M-Fe array and a bridging $\text{S}_2\text{MS}_2$ unit. Electronic structures and crystal and molecular structures of the $[(\text{C}_6\text{H}_5)_4\text{P}]_2[\text{Cl}_2\text{FeS}_2\text{MS}_2\text{FeCl}_2]$ (M = Mo, W) complexes," <i>Inorg. Chem.</i> , 23:741-749, 1984.
LCM	C39	Coucouvanis, "Fe-M-S complexes derived from $\text{MS}_4^{2-}$ anions (M = Mo, W) and their possible relevance as analogues for structural features in the Mo site of nitrogenase," <i>Acc. Chem. Res.</i> , 14:201-209, 1981.
LCM	C40	Coucouvanis, "Syntheses, structures, and reactions of binary and tertiary thiomolybdate complexes containing the $(\text{O})\text{Mo}(\text{S}_x)$ and $(\text{S})\text{Mo}(\text{S}_x)$ functional groups ( $x = 1, 2, 4$ )," <i>Adv. Inorg. Chem.</i> , 45:1-73, 1998.
LCM	C41	Engleka and Maciag, "Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation," <i>J. Biol. Chem.</i> , 267:11307-11315, 1994.
LCM	C42	Fell <i>et al.</i> , "Gut Pathology of Rats Dosed with Tetrathiomolybdate," <i>J. Com. Pathol.</i> , 89:495, 1979.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCED, DATE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C43	Folkman, "Angiogenesis," <i>The Journal of Biological Chemistry</i> , 267(16):10931-10934, 1992.
LCM	C44	Folkman and Klagsbrun, "Angiogenic factors," <i>Science</i> , 23:442-447, 1987.
LCM	C45	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Med.</i> , 1:27-31, 1995.
LCM	C46	Folkman, "The influence of angiogenesis research on management of patients with breast cancer," <i>Breast Cancer Res. Treat.</i> , 36(2):109-118, 1995.
LCM	C47	Folkman, "Antiangiogenic therapy," In: <i>Cancer: Principles and Practice of Oncology</i> , Lippincott-Raven Publishers, pp. 3075-3085, 1997.
LCM	C48	Gooneratne <i>et al.</i> , "An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep," <i>Br. J. Nutr.</i> , 46:469, 1981.
LCM	C49	Gooneratne <i>et al.</i> , "Intravenous administration of thiomolybdate for the prevention and treatment of chronic copper poisoning in sheep," <i>Br. J. Nutr.</i> , 46:457, 1981.
LCM	C50	Gross <i>et al.</i> , "Inhibition of basic fibroblast growth factor-induced angiogenesis and glioma tumor growth <i>in vivo</i> in copper depleted rats," <i>Proceedings of the American Association for Cancer Research</i> , 32:57, Abstract 338, 1991.
LCM	C51	Gullino, "Considerations on the mechanism of the angiogenic response," <i>Anticancer Res.</i> , 6(2):153-158, 1986.
LCM	C52	Hadjikyriacou and Coucouvanis, "New members of the $[\text{Mo}_2(\text{S})_n(\text{S}_2)_{6-n}]^{2-}$ series. Synthesis, structural characterization, and properties of the $[\text{Mo}_2\text{S}_9]^{2-}$ , $[\text{Mo}_2\text{S}_7]^{2-}$ and $[\text{Mo}_2\text{S}_6]^{2-}$ thioanions," <i>Inorg. Chem.</i> , 26:2400-2408, 1987.
LCM	C53	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc II. Validation of Oral $^{64}\text{Cu}$ Copper Uptake with Copper Balance," <i>Am. J. Med. Sci.</i> , 12:344, 1986.

EXAMINER: Leigh C. Maier	DATE CONSIDERED: 4-22-05
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWHI	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1643 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C54	Hill <i>et al.</i> , "Treatment of Wilson's disease with zinc, I: oral zinc therapy regimens," <i>Hepatology</i> , 7:522-528, 1987.
LCM	C55	Hourani and Demopoulos, "Inhibition of S-91 mouse melanoma metastases and growth by D-penicillamine," <i>Laboratory Investigation</i> , 21(5):434-438, 1969.
LCM	C56	Kanatzidis and Coucouvanis, "Structure of Bis(tetraethylammonium) tetrathiomolybdate(VI), $2C_8H_{20}N^+MoS_4^{2-}$ ," <i>Acta Cryst.</i> , C39:835-838, 1983.
LCM	C57	Lee <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc VII. Protection of the Liver for Copper Toxicity by Zinc Induced Metallothionein in a Rat Model," <i>J. Lab. Clin. Med.</i> , 114:639-645, 1989.
LCM	C58	Marshall <i>et al.</i> , "Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer," <i>Clin. Cancer Res.</i> , 3:2347-2354, 1997.
LCM	C59	Merajver <i>et al.</i> , "Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice," <i>Proceedings of Special AACR Conference on Angiogenesis and Cancer</i> , Abstract #B-11, January 22-24, 1998.
LCM	C60	Merajver, "Phase I study of tetrathiomolybdate in metastatic cancer," NIH Grant No. 5R03CA77122-02.
LCM	C61	Mills <i>et al.</i> , "Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats," <i>J. Inorg. Biochem.</i> , 14:189, 1981.
LCM	C62	Mills <i>et al.</i> , "Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate," <i>J. Inorg. Biochem.</i> , 14: 163, 1981.
LCM	C63	Parke <i>et al.</i> , "Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea," <i>Am. J. Pathol.</i> , 130:173-178, 1988.
LCM	C64	Patstone and Maher, "Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors," <i>J. Biol. Chem.</i> , 271:3343-3346, 1996.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/496,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C65	Raju <i>et al.</i> , Ceruloplasmin, copper Ions, and angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:1183-1188, 1982.
LCM	C66	Schapira and Schapira, "Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer," <i>Breast Cancer Res Treat.</i> , 3:223-224, 1983.
LCM	C67	Schuschke <i>et al.</i> , "Short-term dietary copper deficiency does not inhibit angiogenesis in tumours implanted in striated muscle," <i>Br. J. Cancer</i> , 66:1059-1064, 1992.
LCM	C68	Shing, "Heparin-copper biaffinity chromatography of fibroblast growth factors," <i>J. Biol. Chem.</i> , 263:9059-9062, 1988.
LCM	C69	Teo <i>et al.</i> , "Mo, W, and Fe EXAFS of the $[\text{Cl}_2\text{FeS}_2\text{MS}_2\text{FeCl}_2]^{2-}$ (M = Mo, W) dianions. A comparison with the Mo EXAFS of nitrogenase," <i>J. Am. Chem. Soc.</i> , 105:5767-5770, 1983.
LCM	C70	Yoshida <i>et al.</i> , "Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model," <i>Neurosurgery</i> , 37(2):287-292, 1995.
LCM	C71	Yoshida <i>et al.</i> , "Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and D-penicillamine," <i>J. Neurooncol.</i> , 17(2):91-97, 1993.
LCM	C72	Yuzbasiyan-Gurkan <i>et al.</i> , "Treatment of Wilson's Disease with Zinc V. Changes in Serum Levels of Lipase, Amylase and Alkaline Phosphatase in Wilson's Disease Patients," <i>J. Lab. Clin. Med.</i> , 114:520-526, 1989.
LCM	C73	Yuzbasiyan-Gurkan <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc X. Intestinal Metallothionein Induction," <i>J. Lab. Clin. Med.</i> , 120:380-386, 1992.
LCM	C74	Zagzag, "The effects of copper depletion on intracerebral angiogenesis and growth of experimental brain tumors," <i>Dissertation Abstracts International</i> , 53(12B):6160, 1988.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. 4100.001000/DWH	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver, Nathan Ockwig and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: <del>1643</del> 1623
U.S. Patent Documents See Page 1	Foreign Patent Documents	Other Art See Pages 1-9	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C75	Ziche <i>et al.</i> , "Role of Prostaglandin E <sub>1</sub> and Copper in Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:475-482, 1982.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4100.001000	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
	Filing Date: September 3, 1999	Group: <del>1623</del> 1623
U.S. Patent Documents	Foreign Patent Documents	Other Art See Pages 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C76	Brem "Angiogenesis and cancer control: From concept to therapeutic trail," <i>Cancer Control</i> , 6(5):436-458, 1999.
LCM	C77	Brewer and Merajver, "Treatment of metastatic cancer with the anticopper antiangiogenic drug tetrathiomolybdate," <i>J. Invest. Med.</i> , 47(7):223A, 1999.
LCM	C78	Brewer <i>et al.</i> , "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study," <i>Clin. Canc. Res.</i> , 6(1):1-10, 2000.
LCM	C79	International Search Report dated July 4, 2000 (PCT/US99/20374; 4100.001010).
LCM	C80	Merajver, "A Phase I study of oral tetrathiomolybdate (TM) as a decoppering and anti-angiogenesis agent for metastatic cancer," From the Internet at website <a href="http://www.cancer.med.umich.edu/cgi-bin/protocol?9708_701">http://www.cancer.med.umich.edu/cgi-bin/protocol?9708_701</a> , 1998.
LCM	C81	Sergeant and Johnson, "Iron and copper requirements for proliferation and differentiation of a human promyelocytic leukemia cell line (HL-60)," <i>J. Cell. Physiol.</i> , 163:477-485, 1995.
LCM	C82	Shah <i>et al.</i> , "Circular dichroism of carbohydrate-molybdate complexes," <i>Stud. Nat. Prod. Chem.</i> , 15:423-438, 1995.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001000	Serial No. <del>09/389,435</del> 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: September 3, 1999	Group: 1623
U.S. Patent Documents See Pages 1	Foreign Patent Documents See Pages	Other Art See Pages	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
LCM	A7	5,697,902	December 16, 1997	Goldenberg	604	49	
LCM	A8	5,565,491	October 15, 1996	Schieven	514	492	
LCM	A9	5,512,559	April 30, 1996	Skalkos <i>et al.</i>	514	185	
LCM	A10	5,443,816	August 22, 1995	Zamora <i>et al.</i>	424	1.69	
LCM	A11	5,391,547	February 21, 1995	Cole <i>et al.</i>	514	184	
LCM	A12	4,952,607	August 28, 1990	Sorenson <i>et al.</i>	514	589	
LCM	A13	4,766,226	August 23, 1988	Hill <i>et al.</i>	556	18	
LCM	A14	4,678,667	July 7, 1987	Meares <i>et al.</i>	424	85	
LCM	A15	RE 35,458	February 18, 1997	Azuara	556	116	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER: Lugh C. MaierDATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
4100.001099Serial No.  
10/796,782

List of Patents and Publications for Applicant's

Applicant  
Brewer *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
March 09, 2004Group:  
1616 1623U.S. Patent Documents  
See Page 1-2Foreign Patent Documents  
See Page 2Other Art  
See Page 2-7

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
LCM	A16	5,112,598	05/12/92	Biesalski	424	45	
LCM	A17	5,527,533	06/18/96	Tso <i>et al.</i>	424	422	
LCM	A18	5,556,611	09/17/96	Biesalski	424	46	
LCM	A19	5,583,153	12/10/96	Brahn	514	449	
LCM	A20	5,970,974	10/26/99	Van der Linden <i>et al.</i>	128	200.16	
LCM	A21	5,954,047	09/21/99	Armer <i>et al.</i>	128	200.23	
LCM	A22	5,950,619	09/14/99	van der Linden <i>et al.</i>	128	200.16	
LCM	A23	5,698,155	12/16/97	Grosswald <i>et al.</i>	264	402	
LCM	A24	5,639,725	06/17/97	O'Reilly <i>et al.</i>	514	12	
LCM	A25	4,765,539	08/23/88	Noakes <i>et al.</i>	239	3	
LCM	A26	3,916,899	11/04/75	Theeuwes <i>et al.</i>	128	127	
LCM	A27	3,845,770	11/05/74	Theeuwes <i>et al.</i>	128	260	
LCM	A28	4,604,278	08/05/86	Reilly <i>et al.</i>	423	817	
LCM	A29	4,343,746	08/10/82	Anglin <i>et al.</i>	556	57	
LCM	A30	2,909,541	10/20/59	Hugel	260	429	
LCM	A31	6,703,050	03/09/04	Brewer <i>et al.</i>	424	641	
LCM	A32	5,639,757	June 17, 1997	Dow <i>et al.</i>	514	261	
LCM	A33	5,712,291	Jan. 27, 1998	D'Amato	514	323	
LCM	A34	5,753,230	May 19, 1998	Brooks <i>et al.</i>	424	158.1	
LCM	A35	5,972,922	Oct. 26, 1999	Wilks <i>et al.</i>	514	178	

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
LCM	A36	2004/0009237 A1	Jan. 15, 2004	Brewer	424	617	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
LCM	B1	EP 1 107 795 B1	Nov. 27, 2002	EP			
LCM	B2	EP 1 234 585 A2	Aug. 28, 2002	EP			
LCM	B3	WO 00/13712	Mar. 16, 2000	PCT			
LCM	B4	WO 2004/009072	Jan. 29, 2004	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C83	Benjamin <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
LCM	C84	Borgstrom <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>In Vivo</i> ," <i>The Prostate</i> , 35:1-10, 1998.
LCM	C85	Jeannin <i>et al.</i> , "Molecular Architecture of Copper(I) Thiometallate Complexes. Examples of a Cubane with an Extra Face, (NPr <sub>4</sub> ) <sub>3</sub> [MS <sub>4</sub> Cu <sub>4</sub> Cl <sub>5</sub> ]," <i>Inorganic. Chimica. Acta.</i> , 198-200:493-500, 1992.
LCM	C86	Malavé <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngenic Mice," <i>J. Natl. Cancer Inst.</i> , 62(1):83-88, 1979.
LCM	C87	Passaniti <i>et al.</i> , "Methods in Laboratory Investigation," <i>Laboratory Investigation</i> , 67(4):519-528, 1992.
LCM	C88	Sécheresse <i>et al.</i> , "Heterobimetallic Aggregates of Copper(I) with Thio-tungstate and -molybdate. Cation Effect in Aggregation of Ms <sub>4</sub> Cu <sub>4</sub> Cl <sub>5</sub> Units, a Crystallographic Study," <i>J. Chem. Soc. Dalton Trans.</i> , 11:2875-2881, 1991.

EXAMINER: Leigh C. Mair

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C89	Sugiura <i>et al.</i> , "Studies in a Tumor Spectrum," <i>Cancer Research</i> , 15:38-51, 1955.
LCM	C90	Takai <i>et al.</i> , "Preparation, Structure and Properties of Mixed-Metal Trinuclear Complex: (Pr <sub>4</sub> N) <sub>2</sub> [MoO(WS <sub>4</sub> ) <sub>2</sub> ]," <i>Chemistry Letters</i> , 8:645-646, 1996.
LCM	C91	Bajou <i>et al.</i> , "Absence of Host Plasminogen Activator Inhibitor I Prevents Cancer Invasion and Vascularization," <i>Nat. Med.</i> , 4:923-928, 1998.
LCM	C92	Bamba <i>et al.</i> , "Release Mechanisms in Gel Forming Sustained Release Preparations," <i>Int. J. Pharm.</i> , 2:307, 1979.
LCM	C93	Blood <i>et al.</i> , "Tumor Interactions With the Vasculature: Angiogenesis and Tumor Metastasis", <i>Biochim. Biophys. Acta.</i> , 1032:89-118, 1990.
LCM	C94	Brown, "Metal Toxicity and Therapeutic Intervention," <i>Biochem. Soc. Trans.</i> , 30:742- 745 2002.
LCM	C95	Brown, "Copper and Prion Disease," <i>Brain Res. Bull.</i> , 55:165-173, 2001.
LCM	C96	Carri <i>et al.</i> , "Copper-Dependent Oxidative Stress, Alteration of Signal Transduction and Neurodegeneration in Amyothopic Lateral Sclerosis," <i>Funct. Neurol.</i> , 16:181-188, 2001.
LCM	C97	Chakravarty <i>et al.</i> , "Serum Copper in Malignant Neoplasia with Special Reference to the Cervix Uteri," <i>J. Cancer Res. Clin. Oncol.</i> , 108: 312-315, 1984.
LCM	C98	Chambers <i>et al.</i> , "Macrophage Colony-Stimulating Factor Mediates Invasion of Ovarian Cancer Cells Through Urokinase," <i>Cancer Research</i> , 55:1578-1585, 1995.
LCM	C99	Chen <i>et al.</i> , "TNF-RI Signaling: A Beautiful Pathway," <i>Science</i> , 296:1634-1635, 2002.
LCM	C100	Crowley <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> , 90:5021-5025, 1993.
LCM	C101	During <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant; In vivo Characterization," <i>Ann. Neurol.</i> , 25:351-356, 1989.
LCM	C102	Folkman, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> , 175: 409-416, 1972.
LCM	C103	Folkman, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> , 1(2):120-122 1995.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C104	Gnjec <i>et al.</i> , "Transition Metal Chelator Therapy - A potential Treatment For Alzheimer's Disease?" <i>Front Biosci.</i> , 16-23, 2002.
LCM	C105	Goodson, "Medical Applications of Controlled Release" 2:115-138, 1984.
LCM	C106	Gorelik <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l. Cancer Inst.</i> , 65: 1257-1264, 1980.
LCM	C107	Gorelik, <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control-Progression of Postoperative Lung Metastasis," <i>Rec. Results Cancer Res.</i> , 75:20-28, 1980.
LCM	C108	Hanada <i>et al.</i> , "Regulation of Cytokine Signaling and Inflammation," <i>Cytokine Growth Factor Rev.</i> , 13: 413-421, 2002.
LCM	C109	Hanahan <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):355-364, 1996.
LCM	C110	Hilgard <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> , 35:78-86, 1977.
LCM	C111	Howard <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," <i>J. Neurosurg.</i> , 71:105-112, 1989.
LCM	C112	Isakov <i>et al.</i> , "An Immune Response Against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Metas.</i> , 2:12-32, 1982.
LCM	C113	Kleinman <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochem.</i> , 25: 312-318, 1986.
LCM	C114	Koch <i>et al.</i> , "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis," <i>Science</i> , 258:1798-1801, 1992.
LCM	C115	Kowalik-Jankowska <i>et al.</i> , "Possible Involvement of Copper (II) in Alzheimer Disease," <i>Environ. Health Perspect.</i> , 5:869-870, 2002.
LCM	C116	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> , 23:61-126, 1983.
LCM	C117	Langer, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1533, 1990.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C118	Levy <i>et al.</i> , Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> , 228:190-192, 1985.
LCM	C119	Llanos <i>et al.</i> , "The Molecular Basis of Copper Homeostasis and Copper-Related Disorders," <i>DNA Cell Biol.</i> , 21:259-270, 2002.
LCM	C120	Loskutoff <i>et al.</i> , "A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM," <i>Ann. N.Y. Acad. Sci.</i> , 902:272-282, 2000.
LCM	C121	Malave <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Cancer Inst.</i> , 62:83-88, 1979.
LCM	C122	Mandinov <i>et al.</i> , "Copper Chelation Represses the Vascular Response To Injury" <i>PNAS</i> , 100:6700-6705, 2003.
LCM	C123	Maynard <i>et al.</i> , "Overexpression of Alzheimer's Disease Amyloid- $\beta$ Opposes the Age-Dependent Elevations of Brain Copper and Iron," <i>J. Biol. Chem.</i> , 277(47):44670-44676, 2002.
LCM	C124	Millauer <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>In vivo</i> ," <i>Cancer Res.</i> , 56:1615-1620, 1996.
LCM	C125	Min <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , 56:2428-2433, 1996.
LCM	C126	Miyake <i>et al.</i> , "Transforming Growth Factor- $\beta$ 1 Stimulates Contraction of Human Glioblastoma Cell-Mediated Collagen Lattice Through Enhanced $\alpha$ 2 Integrin Expression," <i>J. Neuropathol. Exp. Neurol.</i> , 59:18-28, 2000.
LCM	C127	Nguyen <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> , 47:31-40, 1994.
LCM	C128	Odedra <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> , 49:111-124, 1991.
LCM	C129	Osawa <i>et al.</i> , "Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF- $\kappa$ B and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes," <i>Infect. Immun.</i> , 70:6294-6301, 2002.
LCM	C130	Pan <i>et al.</i> , "Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis," <i>Cancer Res.</i> , 62: 4854-4859, 2002.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)	Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant Brewer <i>et al.</i>	
	Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C131	Parish <i>et al.</i> , "A Basement-Membrane Permeability Assay Which Correlates with the Metastatic Potential of Tumor Cells," <i>Int. J. Cancer</i> , 52:378-383, 1992.
LCM	C132	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea" <i>Am. J. Pathol.</i> , 130:173-178, 1988.
LCM	C133	Passaniti <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab. Invest.</i> , 67:519-528, 1992.
LCM	C134	Patstone <i>et al.</i> , "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271(7):3343-3346, 1996.
LCM	C135	Perry <i>et al.</i> , "The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders," <i>CNS Drugs</i> , 16:339-352, 2002.
LCM	C136	Rabbani <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> By a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)," <i>Int. J. Cancer</i> , 63:840-845, 1995.
LCM	C137	Redman <i>et al.</i> , "Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer," <i>Clin. Cancer Res.</i> , 9:1666-1672, 1996.
LCM	C138	Rupnick <i>et al.</i> , "Adipose Tissue Mass Can Be Regulated Through the Vasculature," <i>Proc. Natl. Acad. Sci.</i> , 99:10730-10735, 2002.
LCM	C139	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 321:574, 1989.
LCM	C140	Schnaper <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , 165:107-118, 1995.
LCM	C141	Sefton, "Implantable Pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , 14(3):201-240, 1987.
LCM	C142	Sen <i>et al.</i> , "Copper-Induced Vascular Endothelial Growth Factor Expression and Wound Healing," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:H1821-H1827, 2002.
LCM	C143	Shockley <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> , 617:367-382, 1991.
LCM	C144	Strausak <i>et al.</i> , "Copper in Disorders with Neurological Symptoms: Alzheimer's, Menkes, and Wilson Diseases," <i>Brain Res. Bull.</i> , 55:175-185, 2001.

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: <del>1616</del> 1623
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2	Other Art See Page 2-7	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LCM	C145	Talmadge <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Cancer Inst.</i> , 69:975-980, 1982
LCM	C146	Thakur <i>et al.</i> , "Indium-111-Labeled Leukocytes for the Localization of Abscesses: Preparation, Analysis, Tissue Distribution, and Comparison with Gallium-67 Citrate in Dogs," <i>J. Lab. Clin. Med.</i> , 89:217-228, 1977.
LCM	C147	Treat <i>et al.</i> , in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, 353-365, 1989.
LCM	C148	Van Golen <i>et al.</i> , "Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma," <i>Neoplasia</i> , 4(5):373-379, 2002.
LCM	C149	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Develop. Indus. Pharm.</i> , 26(7):665-708, 2000.
LCM	C150	Verschoye <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 80, Suppl. 2, 96, 1999.
LCM	C151	Volpert <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> , 98:671-679, 1996.
LCM	C152	Xing <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> , 67:423-429, 1996.
LCM	C153	International Search Report for PCT/US03/003210, mailed December 18, 2003 (4100.003210).
LCM	C154	International Search Report for PCT/US03/23031, mailed June 29, 2004

EXAMINER: Leigh C. Maier

DATE CONSIDERED: 4-22-05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.